UnknownPhase 2

Bacillus Clausii in Liver Transplantation

Egypt60 participantsStarted 2021-09-07

Plain-language summary

A prospective, randomized, controlled study of the safety and efficacy of using Bacillus clausii probiotic oral preparation to decrease the incidence of infection during the first 30 days after living donor liver transplantation surgery.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 - 65 years. * Patients suffering from end stage liver disease (ESLD) with any etiology listed on waiting list and accepting to volunteer in the study with the informed consent. * Patients not suffering from any active infection at the start of the study. Exclusion Criteria: * Patients with poorly controlled autoimmune disease on immunosuppression before transplantation. * Patients who undergo combined kidney-liver transplantation. * Patients with severe renal insufficiency (creatinine clearance \<50 ml/min). * Patients with intestinal obstruction (ileus). * Patients with cerebral disorders with danger of aspiration. * Patients with roux en Y-anastomosis. * Patients with cystic fibrosis. * Retransplantation.

What they're measuring

infection and mortality rates

Timeframe: up to 30 days post-operatively

Trial details

NCT IDNCT05047406

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-30

View on ClinicalTrials.gov More Transplantation Infection trials